Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NTZ 500mg BID on top of SOC
NTZ on top of SOC · 1 trial · 2 indications
Safety defined as the incidence, relatedness, and severity (NCI-CTCAE v6.0 grade) of TEAEs including SAEs (comprising the evaluation of vital signs, ECGs, and laboratory parameters).
| Arm | Type | Description |
|---|---|---|
| NTZ 500mg BID on top of SOC | EXPERIMENTAL | Treatment period NTZ 500mg BID on top of SOC during 7 days. |
| Name | Type | Description |
|---|---|---|
| NTZ 500mg BID on top of SOC | DRUG | Treatment period NTZ 500mg BID on top of SOC |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Participants with liver cirrhosis of any underlying etiology (liver cirrhosis diagnosed by standard clinical criteria, imaging findings, and/or histology) * Recent acute clinica...
NTZ on top of SOC is an investigational small molecule being studied for the treatment of acute decompensation of liver cirrhosis, including patients at high risk of progression to acute-on-chronic liver failure or with established acute-on-chronic liver failure. It is administered at a dose of 500 mg twice daily in addition to standard of care.
NTZ on top of SOC is being developed by Genfit SA Sponsored ADR, which trades under the ticker GNFT. The company is conducting a Phase 2 clinical trial of this investigational therapy in patients with acute decompensation of liver cirrhosis.
NTZ on top of SOC is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 study is designed to evaluate the therapy in patients with acute decompensation of liver cirrhosis at high risk of progression to acute-on-chronic liver failure.
NTZ on top of SOC is being evaluated in one Phase 2 clinical trial with the identifier NCT07694297. This study is not yet recruiting and plans to enroll 16 participants. The trial is uncontrolled, meaning there is no comparator arm, and it is open to adults aged 18 years and older.
Yes, NTZ on top of SOC is also known as NTZ 500mg BID on top of SOC. The alternative name specifies the dosing regimen of 500 mg taken twice daily in addition to standard of care, as used in the Phase 2 clinical trial for acute decompensation of liver cirrhosis.